Business
INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market
SARASOTA, Fla., March 24, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on
About this update from Invo Fertility, Inc.
[{"type":"text","content":"SARASOTA, Fla., March 24, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) (\"INVO\" or the \"Company\"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (\"IVC\") procedure it enables, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor to purchase 3,680,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company has also agreed to issue and sell warrants to purchase up to an aggregate of 5,520,000 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and warrant will be $0.815. The warrants will be immediately exercisable, expire on the eight-year anniversary of the issuance date and will have an exercise price of $0.63 per share.\n\n \n \n \n \n \n \n\n \nThe gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $3.0 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about March 27, 2023, subject to the satisfaction of customary closing conditions.\nMaxim Group LLC is acting as the sole placement agent for the offering.\nThe shares of common stock (or pre-funded warrants in lieu thereof) are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-255096), which was declared effective by the United States Securities and Exchange Commission (\"SEC\") on April 16, 2021. The warrants issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the \"Act\"), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws.\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solic...